Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Article
Next
Article

Letter from the Editor-in-Chief

Authors: Abd Tahrani
European Endocrinology, 2017;13(1):12 DOI: https://doi.org/10.17925/EE.2017.13.01.12

Abstract

Abd Tahrani is a National Institute for Health Research (NIHR) Clinician Scientist at the University of Birmingham (UOB), and a Honorary Consultant Endocrinologist and the lead for weight management research and diabetic neuropathy services at Heart of England NHS Foundation Trust, Birmingham, UK. He gained MD in 1998, MRCP (UK) in 2003, MMedSci from Keele University in 2008, CCT in diabetes and endocrinology in 2012 and a PhD in 2012 from the UOB.

I am delighted to take on the role of Editor-in-Chief for European Endocrinology and would like to take this opportunity to introduce myself. I’m a National Institute for Health Research Clinician Scientist at the University of Birmingham and an Honorary Consultant Physician in Diabetes and Endocrinology and Obesity at Heart of England NHS Foundation Trust. I’m also the lead for weight management research and diabetic neuropathy at Heart of England NHS Foundation Trust. My career started in the UK in 2000, and since then I have obtained a Master’s in Medical Sciences from Keele University, a PhD at the University of Birmingham, a special certification in Obesity Education and Prevention from the World Obesity Federation, and I was also awarded their National Fellowship.

I have four main areas of research. The first is the metabolic impact of sleep-related disorders, particularly in the fields of diabetes, obesity and vascular disease. The second is understanding the pathogenesis and developing new treatments for diabetes-related microvascular complications. The third area is obesity management, which extends from lifestyle interventions to bariatric surgery. Finally, I am interested in the pharmacology of type 2 diabetes.

The last year has been an exciting one for the field of endocrinology. The publication of the cardiovascular outcome trials for antidiabetic therapies, including LEADER, EMPA-REG and SUSTAIN, advanced our understanding of the impact of these new therapies on diabetes-related macrovascular as well as microvascular complications.

European Endocrinology is a unique resource for presenting meetings and satellite symposiums. It has a distinguished Editorial Board, including key opinion leaders with international reputations. It has also published high-quality articles written by experts in the field of diabetes, endocrinology and obesity. In addition, its open access format allows the articles to be readily available at the time of publication to the research community and the public. Over the next year we will focus on increasing the multimedia content and will work with the Editorial Board to increase the variety of submissions to European Endocrinology. I look forward to working with everyone involved in developing the journal.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchendocrinology is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.